Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Status Terminated

Clinical Trial Summary

This clinical trial is for patients with Hodgkin Lymphoma that has not responded to standard treatment. The purpose of this study is to determine what effects, good or bad, Temsirolimus has on Hodgkin Lymphoma. The study will also determine whether Temsirolimus is tolerated in patients with Hodgkin Lymphoma who have been previously treated with chemotherapy.

Clinical Trial Description

Temsirolimus 25 mg IV infusion will be given once weekly on days 1, 8, 15 and 22 of each cycle. Patients will be assessed for response with CT scans after the second cycle, and then after every other cycle until disease progression is confirmed.

Patients will be treated with Temsirolimus until disease progression, or up to six cycles. Continuation of therapy beyond cycles is at the discretion of the investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00838955
Study type	Interventional
Source	Loyola University
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2009
Completion date	October 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03776864` - Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Terminated	`NCT01699581` - Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant	Phase 2
Completed	`NCT00784537` - High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients	Phase 2/Phase 3
Completed	`NCT00333190` - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation	N/A
Recruiting	`NCT05355051` - A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma	Phase 2
Completed	`NCT00520130` - Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System	Phase 1/Phase 2
Withdrawn	`NCT01316146` - Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)	Phase 1
Completed	`NCT02223052` - Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies	Phase 1
Completed	`NCT02581007` - Reduced Intensity Conditioning Transplant Using Haploidentical Donors	Phase 2
Terminated	`NCT01745913` - Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies	Phase 2
Recruiting	`NCT04665063` - A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma	N/A
Recruiting	`NCT02259556` - CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas	Phase 1/Phase 2
Completed	`NCT02003625` - Meloxicam vs Placebo for Mobilization	Phase 2
Terminated	`NCT01742793` - An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)	Phase 1
Completed	`NCT01402687` - SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)	N/A
Terminated	`NCT00901303` - Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma	N/A
Completed	`NCT00283439` - A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma	Phase 1/Phase 2
Completed	`NCT01272817` - Nonmyeloablative Allogeneic Transplant	N/A